Skip to content

US · BIVI · BIOTECHNOLOGY

BioVie Inc. (BIVI) intrinsic value and stock valuation

$0.80as of 2026-11-21 · Mkt cap 15.39M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioVie Inc. DCF and intrinsic value

InvestorsCraft values BIVI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BIVI’s statements →

BioVie Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carson City, NV 89703 bioviepharma.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-17.54M
20132025
Free cash flow
-$-19.03M
20132025
Total equity
$19M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-18.07M-$-32.18M-$-45.08M-$-27.25M-$-138.05M
Net income-$-17.54M-$-32.12M-$-50.26M-$-26.08M-$-130.25M
EPSd-$-11.85M-$-71.38M-$-157.06M-$-104.32M-$-1.09B
Operating cash flow-$-19.03M-$-27.95M-$-40.25M-$-18.99M-$-10.45M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-19.03M-$-27.95M-$-40.25M-$-18.99M-$-10.45M
Total assets$21.6M$25.2M$35.1M$20.1M$6.05M
Total debt$350K$6.11M$14.4M$12.3M$0.00
Net debt-$-17.19M-$-17.73M-$-5.04M-$-6.38M-$-4.51M
Total equity$19M$15.5M$15.3M$3.67M$5.05M
Cash and short-term investments$17.5M$23.8M$33.9M$18.6M$4.51M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$230K$0.00$0.00$0.00$0.00
Gross profit-$-230K$0.00$0.00$0.00$0.00
Research and development expenses$9.27M$23.1M$33.3M$17.3M$133.2M
Selling, general and administrative expenses$8.57M$0.00$11.6M$0.00$0.00
Other expenses$0.00$9.08M$230K$9.99M$4.87M
Operating expenses$17.8M$32.2M$45.1M$27.3M$138.1M
Cost and expenses$18.1M$32.2M$45.1M$27.3M$138.1M
Interest income$850K$1.14M$560K$40K$20K
Interest expense$330K$2.89M$4.3M$2.16M$560K
Depreciation and amortization$230K$230K$230K$230K$230K
Ebitda-$-16.98M-$-29M-$-45.73M-$-23.69M-$-129.46M
Operating income-$-18.07M-$-32.18M-$-45.08M-$-27.25M-$-138.05M
Total other income/expenses, net$520K$60K-$-5.18M$1.17M$7.8M
Income before tax-$-17.54M-$-32.12M-$-50.26M-$-26.08M-$-130.25M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-17.54M-$-32.12M-$-50.26M-$-26.08M-$-130.25M
Weighted average shares outstanding$1.48M$450K$320K$250K$120K
Weighted average diluted shares outstanding$1.48M$450K$320K$250K$120K
Balance sheet
20252024202320222021
Cash and short-term investments$17.5M$23.8M$33.9M$18.6M$4.51M
Net receivables$2.1M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20.7M$24.1M$34M$18.8M$4.61M
Property, plant and equipment, net$340K$410K$80K$120K$0.00
Goodwill and intangible assets$520K$750K$980K$1.21M$1.44M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$860K$1.16M$1.06M$1.33M$1.44M
Total assets$21.6M$25.2M$35.1M$20.1M$6.05M
Accounts payable$0.00$0.00$0.00$2.44M$1M
Short-term debt$70K$5.76M$9.15M$40K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.27M$9.35M$14.5M$4.17M$1M
Long-term debt$280K$350K$5.27M$12.2M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$280K$350K$5.27M$12.3M-$0.00
Capital lease obligations$350K$410K$90K$130K$0.00
Total liabilities$2.55M$9.7M$19.8M$16.4M$1M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-352.14M-$-334.23M-$-301.23M-$-250.97M-$-224.89M
Accumulated other comprehensive income (loss)$0.00$0.00$180K$0.00$0.00
Total equity$19M$15.5M$15.3M$3.67M$5.05M
Total investments$0.00$0.00$14.5M$0.00$0.00
Total debt$350K$6.11M$14.4M$12.3M$0.00
Net debt-$-17.19M-$-17.73M-$-5.04M-$-6.38M-$-4.51M
Cash flow statement
20252024202320222021
Net income-$-17.54M-$-32.12M-$-50.26M-$-26.08M-$-130.25M
Depreciation and amortization$230K$230K$230K$230K$230K
Stock-based compensation$2.47M$4.66M$6.38M$6.19M$3.02M
Change in working capital-$-4.4M-$-90K-$-270K$2.75M$20K
Accounts receivable-$-2.1M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-19.03M-$-27.95M-$-40.25M-$-18.99M-$-10.45M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$14.5M-$-14.3M$0.00$0.00
Common stock issued$15.7M$27.8M$55.4M$18.5M$15.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.7M$17.8M$55.4M$33.1M$14.9M
Net change in cash-$-6.3M$4.38M$820K$14.1M$4.47M
Cash at end of period$17.5M$23.8M$19.5M$18.6M$4.51M
Operating cash flow-$-19.03M-$-27.95M-$-40.25M-$-18.99M-$-10.45M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-19.03M-$-27.95M-$-40.25M-$-18.99M-$-10.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioVie Inc.

        BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

        CEO
        Cuong Viet Do
        Employees
        13
        Beta
        0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of BioVie Inc. (BIVI)?

        InvestorsCraft does not currently publish an intrinsic value for BIVI. How the IC value is calculated.

        Is BIVI undervalued?

        InvestorsCraft does not publish an undervaluation signal for BIVI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.